What the evidence shows
According to PubMed, a 2022 systematic review and meta-analysis of 76 randomized clinical trials involving over 103,000 patients found that GLP-1 receptor agonist use was associated with a significantly increased risk of gallbladder or biliary disease overall (relative risk 1.37), including specifically cholelithiasis (gallstones, RR 1.27), cholecystitis (gallbladder inflammation, RR 1.36), and broader biliary disease (RR 1.55) (He et al., JAMA Internal Medicine, 2022, DOI (external link)). A more recent, larger 2025 meta-analysis of nearly 100,000 patients confirmed this pattern, finding a 26% increase in gallbladder disorders with GLP-1 use, alongside broader cardiovascular benefits (Galli et al., JACC, 2025, DOI (external link)).
Why the risk is elevated
Two factors appear to drive this risk, and they compound each other:
- Rapid weight loss itself is an independently well-established risk factor for gallstone formation, regardless of method — this happens with bariatric surgery and aggressive dieting too, not just GLP-1 medications.
- The medications may have a direct effect on gallbladder motility and bile composition, separate from weight loss alone, though this mechanism is less definitively established than the weight-loss-driven pathway.
Notably, the 2022 meta-analysis found the risk was significantly higher specifically in trials using GLP-1s for weight loss (RR 2.29) compared with trials for diabetes or other conditions (RR 1.27) — and higher at higher doses and with longer duration of use, suggesting the risk tracks closely with the magnitude and duration of weight-loss treatment.
What symptoms to watch for
Gallstone or gallbladder disease symptoms include sudden, severe pain in the upper right abdomen (often after eating, especially fatty food), pain that may radiate to the back or shoulder, nausea or vomiting alongside the pain, and fever. These symptoms warrant prompt medical attention rather than waiting to see if they pass — unlike routine GI side effects, this isn't something to manage with home strategies.
What this means practically
This isn't a reason to avoid GLP-1 treatment for most people — both meta-analyses found the overall risk increase, while statistically significant, still reflects gallbladder disease as a relatively uncommon event overall, and the 2025 analysis found GLP-1s reduced serious adverse events and mortality overall despite the gallbladder and GI risk increase. It is a reason to know the specific warning signs and not dismiss upper right abdominal pain as routine GI discomfort.
The bottom line
Gallbladder and biliary disease is a real, well-documented risk with GLP-1 treatment — driven by both rapid weight loss and a possible direct drug effect — that rises with higher doses and longer treatment duration. Knowing the specific symptoms (severe upper right abdominal pain, especially after eating) is the most useful takeaway, since this is one GI-adjacent symptom pattern that warrants prompt medical attention rather than a wait-and-see approach.